Kadouch J A, van Rozelaar L, Karim R B, Hoekzema R
Department of Dermatology, VU Medical Centre, Amsterdam, The Netherlands.
Int J STD AIDS. 2013 Sep;24(9):685-94. doi: 10.1177/0956462412474539. Epub 2013 Jul 19.
Combination antiretroviral therapy (CART) reduces the mortality and morbidity in HIV-infected patients. However, facial lipoatrophy (FLA) is one of the well-known side-effects of this treatment and subsequently imposes major problems for HIV-infected patients. In the last decade, ample experience has been obtained with both local therapeutic options as well as possible systemic treatment options. Soft tissue fillers are a relatively simple and efficient treatment option for FLA. Especially, the biodegradable semi-permanent fillers combine a good effect with durability and an acceptable safety profile. The best way to prevent or restrict the development of FLA remains the exclusion of thymidine analogue nucleoside reverse-transcriptase inhibitors from the CART schedule.
联合抗逆转录病毒疗法（CART）可降低HIV感染患者的死亡率和发病率。然而，面部脂肪萎缩（FLA）是这种治疗众所周知的副作用之一，随后给HIV感染患者带来了重大问题。在过去十年中，无论是局部治疗方案还是可能的全身治疗方案都积累了丰富的经验。软组织填充剂是治疗FLA相对简单有效的选择。特别是，可生物降解的半永久性填充剂兼具良好效果、持久性和可接受的安全性。预防或限制FLA发展的最佳方法仍然是在CART方案中排除胸苷类似物核苷逆转录酶抑制剂。
